ellaturner

The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030, predicts Roots Analysis

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries